Full Title:

Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer's Disease in Patients with

Rheumatoid Arthritis and Psoriasis

Short Title:

TNF Blocking Agents Reduce Risk for Alzheimer's Disease in Patients with Rheumatoid Arthritis and Psoriasis

Authors:

Mengshi Zhou[1], Rong Xu[1], David C. Kaelber[1,2], and Mark E. Gurney[3]

[1] Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve

University, Cleveland, OH44106

[2]Departments of Internal Medicine and Pediatrics and the Center for Clinical Informatics Research and Education,

The MetroHealth System, Cleveland, OH, USA

[3]Tetra Therapeutics, 38 Fulton Street West, Grand Rapids, MI 49503

Corresponding Authors:

Rong Xu

Email:rxx@case.edu

Mark Gurney

Email: mark@tetratherapeutics.com

Abstract

This large, retrospective case-control study of electronic health records from 56 million unique adult patients

examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent reduced risk for

Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases

which are mediated in part by TNF and for which a TNF blocker is an approved treatment.   The analysis

compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF

blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. RA increased the risk for AD

(Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10), P-value <0.0001) as did psoriasis

(AOR = 1.37 (1.31-1.42), P <0.0001), ankylosing spondylitis (AOR = 1.57 (1.39-1.77), P <0.0001) ,

inflammatory bowel disease (AOR = 2.46 (2.33-2.59), P < 0.0001), ulcerative colitis (AOR = 1.82 (1.74-1.91), P

<0.0001), and Crohn's disease (AOR = 2.33 (2.22-2.43), P <0.0001). The risk for AD in patients with RA was

reduced by treatment with etanercept (AOR = 0.34 (0.25-0.47), P <0.0001), adalimumab (AOR = 0.28 (0.19-

0.39), P < 0.0001), and infliximab (AOR = 0.52 (0.39-0.69), P <0.0001). Methotrexate also reduced risk for

Alzheimer's disease (AOR = 0.64 (0.61-0.68), P <0.0001), while further risk reduction was achieved in patients

with a prescription history for both a TNF blocker and methotrexate. Etanercept and adalimumab also reduced

the risk for AD in patients with psoriasis: AOR = 0.47 (0.30-0.73 and 0.41 (0.20-0.76), respectively. There was

no effect of gender or race, while younger patients showed greater benefit from a TNF blocker than did older

patients. This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD

through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF

blocking agent.

Introduction

Alzheimer's disease (AD) is the most common cause of dementia. Characteristic pathology in brain includes the presence of plaques (deposits of amyloid-β peptide) and tangles (intraneuronal deposits of hyperphosphorylated tau protein) [1, 2]. These occur in hippocampus and associational cortex, regions of the brain important for cognitive function. Accumulation of amyloid plaque occurs over many years and generally precedes accumulation of intraneuronal tangles and cognitive dysfunction [2]. Progression of disease is associated with neuronal degeneration, cortical thinning, and deepening and severe cognitive impairment. Neuroinflammatory changes around the amyloid plaques include reactive astrocytosis and microglial cell activation [3]. Microglia cells, the resident macrophages in the brain, derive embryonically from the same myeloid stem cells in bone marrow that give rise to monocytes and macrophages elsewhere in the body [4]. Macrophages are one of the important drivers of systemic inflammation through the overproduction of tumor necrosis factor (TNF) and other proinflammatory cytokines [5]. In the brain, elevation of TNF in cerebrospinal fluid collected from subjects with mild cognitive impairment is associated with progression to Alzheimer's disease at 6 months follow up [6]. Multiple lines of evidence indicate that TNF may trigger or amplify aberrant microglia signaling in the brain [7-10] and thereby contribute to Alzheimer's disease pathogenesis.

Multiple systemic inflammatory diseases are caused in part by the production of TNF by activated macrophages and these can be treated effectively with a TNF blocking agent. Approved indications for TNF blockers include rheumatoid arthritis (RA), ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis (UC) and Crohn's disease (CD) which are subtypes of inflammatory bowel disease (IBD) [5]. Inflammation in RA is localized to the synovial lining of the joints where synovial cell proliferation leads to a thickening of the lining, infiltration of activated macrophages and other inflammatory cells, elevated production of TNF, and irreversible destruction of the joint architecture and function [11]. TNF produced systemically may directly enter the brain through receptor-mediated transcytosis [12]. In mice, both types of TNF receptors, TNFR1 and TNFR2, participate in the transport of TNF across the blood brain barrier while other proteins present in blood are excluded. Thus, systemic production of TNF may directly affect inflammatory processes in the brain relevant to Alzheimer's disease.

We therefore sought to test the hypothesis that systemic inflammation involving TNF is associated with increased

risk for Alzheimer's disease and that this could be mitigated by a TNF blocking agent. A previous case-control

study of 8.5 million insured adults in the United States (US) reported increased risk for Alzheimer's disease in

patients with RA and that etanercept, a TNF blocking agent prescribed for the treatment of RA, was associated

with reduction of risk for AD (Adjusted Odds Ratio (AOR) = 0.30; 95% Confidence Interval (CI) = 0.08-0.87. *P*-

value = 0.02) [13].   The study was based on 9,253 patients with Alzheimer's disease in the private insurance

database.

Alzheimer's disease is underrepresented in US private insurance databases as most patients with Alzheimer's

disease are older than 65, an age in the US when the majority of Americans transition from employer provided,

private insurance to Medicare, a national health insurance program. We therefore undertook a retrospective study

using the IBM Watson Healthcare Explorys Cohort Discovery platform which contains electronic health records

(EHR) from patients with private insurance, Medicare and Medicaid. The Explorys Cohort Discovery platform

contains the de-identified EHR of nearly 56 million unique patients with age $\geq$ 18 years from 26 healthcare

systems across all 50 states in the US from 1999 to 2018. We expanded our analysis to other inflammatory

diseases and to additional drugs in the class of TNF blocking agents to assess their potential effect on risk for

Alzheimer's disease. Recent studies have shown that with this unique EHR database and built-in informatics

tools, large hypothesis-driven case-control studies can be undertaken [14-16]. Sufficient patient EHR were

available for the evaluation of co-morbid AD in patients with RA or psoriasis that were treated with etanercept,

adalimumab, and infliximab. Etanercept (Enbrel®) is a fusion of soluble TNF receptor 2 with the Fc portion of

mouse immunoglobulin G1 [17]. Adalimumab (Humira®) is a fully human, anti-TNF monoclonal antibody [18],

while infliximab (Remicade®) is a chimeric mouse-human monoclonal antibody in which the antigen combining

region of a mouse anti-TNF monoclonal antibody was fused to a human Fc domain [19]. Such large, biologic

drugs are not expected to have good access to brain after subcutaneous or intravenous injection due to exclusion

of protein macromolecules by the blood brain barrier [12, 20].

Methods

Database description

We performed a retrospective case-control study using de-identified population-level EHR collected by the IBM

Watson Health Explorys Cohort Discovery platform from 360 hospitals and 317,000 providers [15]. The de-

identified data are accessed using the Explore application from the Explorys Cohort Discovery platform. Explorys

collects data from multiple health information system using a health data gateway (HGD) server. The data

collected include patient demographics, disease diagnoses, medication history, findings, procedures, and

laboratory test results. The EHR are de-identified in accordance with the Health Insurance Portability and

Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health

(HITECH) Act standards. After the de-identification process, the HGD server normalizes the data to facilitate

search using the clinical ontologies from the United Medical Language System (UMLS) [21]. Specifically,

systematized nomenclature of medicine – clinical terms (SNOMED-CT) are used to map disease diagnoses,

clinical findings, procedures, and pharmacological drug classes [22]; individual drug names are mapped into

RxNorm [23], and lab results and measurements are mapped into logical observation identifiers names and codes

(LOINC) [24]. For HIPAA-compliant, statistical de-identification, the IBM Watson Health Explorys Cohort

Discovery platform does not report cohort counts less than 10. At the time of the study, the Explorys Cohort

Discovery platform contained over 64 million unique patients among which nearly 56 million were over 18 years

of age (21 % of the U.S. population).

Study population

Patients were drawn from the Explorys platform and categorized based on their disease diagnoses and medication

history. We defined patients as having Alzheimer's disease if they had any encounter diagnosis in their

contributing EHR of Alzheimer's disease based on the SNOMED-CT disease name. A similar method was

applied for identifying patients with the broader diagnosis of dementia. Since Alzheimer's disease is a

subdiagnosis of dementia within SNOMED-CT, the group of patients with dementia included all patients with a

diagnosis of dementia (**Table 1**). SNOMED-CT disease names also were used to identify patients diagnosed with

one of eight inflammatory diseases: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis,

inflammatory bowel disease, ulcerative colitis, and Crohn's disease.   Inflammatory bowel disease is a SNOMED-

CT diagnostic category that includes all patients with the subdiagnosis of ulcerative colitis but excludes patients

with Crohn's disease. Patients diagnosed with more than one inflammatory disease were excluded from the

analysis. For example, a patient diagnosed with rheumatoid arthritis who also was diagnosed with ankylosing

spondylitis, psoriasis, psoriasis with arthropathy, inflammatory bowel disease, ulcerative colitis, or Crohn's

disease was excluded from the analysis. The effects of each inflammatory disease on Alzheimer's disease or

dementia were compared to a non-inflammatory disease group that comprised patients who had no diagnosis of

any of the eight inflammatory diseases.

A patient was considered "taking a medication" if at least one outpatient prescription for the medication had been

written for the patient. Patients who took a drug treatment were identified by searching the generic drug names.

The Explorys Cohort Discovery platform has standardized all drug names to their generic names based on

RxNorm. There are five TNF blocking agents that have been approved by US Food and Drug Administration

(FDA): etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab. Sufficient numbers of subjects

(at least 10 patients in each cell in a two by two table for at least one strata) were available to study the effects of

etanercept, adalimumab, and infliximab. For the analysis, subjects were included if they were treated with a single

TNF blocker but were excluded if they were treated with two or more TNF blocking drugs. For example, in the

etanercept group, patients who also were prescribed adalimumab, infliximab, certolizumab pegol, or golimumab

were excluded. Similarly, in the methotrexate group, patients who also were prescribed at least one of the TNF

blocking agents were excluded. The effects of the TNF blockers were assessed with and without a prescription

history for methotrexate. The effects of each drug treatment on the risk for Alzheimer's disease or dementia

including Alzheimer's disease were compared to a control group of patients who did not have prescriptions for

any TNF blocking agents or for methotrexate. **Figure 1** is a screenshot that illustrates how the Explorys Cohort

Discovery platform was used to perform cohort identification for the case-control study using the Explore fast

search tool.

Statistical Analysis

The crude Odds Ratio (OR), 95% Confidence Interval (CI), and *P*-values were calculated using the Fisher exact

test in univariate analysis. The Adjusted OR (AOR), 95% CI and *P*-values were calculated using the Cochran-

Mantel-Haenszel (CMH) method by controlling for confounding factors such as age, gender, and race [25].

Statistical tests were conducted with significance set at *P*-value < 0.05 (two-sided).

To compute the AORs of dementia for the drug use group versus the corresponding non-drug use group, or for the

inflammatory disease group versus the non-inflammatory disease group, we first calculated the OR for each of the

8 strata (tabulation of 2 age groups: 18-65, and >65 years; 2 genders: male and female; and 2 races: Caucasian and

Non-Caucasian) and then calculated the weighted average across all strata using the CMH method [25]. The AOR

comparing the drug use group versus the non-drug use group were calculated separately in patients with a

diagnosis code of rheumatoid arthritis and psoriasis. There were not enough patients (at least one cell in a two by

two table have counts lower than 10 for all the strata) to test the effect of TNF blocking agents in patients with the

other inflammatory diseases. To assess the effects of gender, age, and race on the risk associations between the

therapeutic drugs and dementia, we separately calculated the crude OR of dementia among the 2 age groups, 2

gender groups, and 2 race groups. To adjust for methotrexate prescription status in psoriasis patients, we

separately calculated the crude OR for a diagnosis of Alzheimer's disease or dementia among 16 strata (tabulation

of 2 age groups, 2 gender groups, 2 race groups, and 2 methotrexate groups (history of methotrexate or no

methotrexate) and then calculated the weighted average across all strata using the CMH method [25].

Similarly, the AOR of co-morbid Alzheimer's disease for each inflammatory disease group versus the control no-

inflammatory disease group were calculated by weighted average across all 8 strata. The AOR comparing the

drug use group with non-drug use group on Alzheimer's disease were only calculated among patients > 65 years

due to the limited sample size for patients <65 years that were diagnosed with both Alzheimer's disease and a

TNF-related inflammatory disease. Specifically, the AORs of Alzheimer's disease were the weighted average of

OR across all 4 strata (tabulation 2 genders: male and female; and 2 races: Caucasian and non-Caucasian) using

the CMH method [25].

We used patient insurance types (e.g., Medicaid, Medicare, private insurance) as a proxy for their socioeconomic

status. We calculated the AOR of dementia by taking the insurance status into account. We performed this

procedure for patients with age between 18-65 and patients with age > 65 years old separately, since the majority

of patients with age > 65 use Medicare insurance. For patients 18 - 65 years old, the AOR were calculated by

controlling for gender (male and female), race (Caucasian and non-Caucasian), and insurance status (private

versus no-private insurance). For patients > 65 years old, the AOR were calculated by controlling for gender

(male and female), race (Caucasian and non-Caucasian), and insurance status (Medicare versus no-Medicare).

Results

Structure of the Study Population

The IBM Watson Health Explorys Cohort Discovery platform contained EHR from 55,902,250 unique adult

patients (≥ 18 years of age) at the time of the study. The baseline characteristics of the study population are

presented in **Table 1**. The proportion of female patients is slightly higher than the proportion of male patients

(54.88% versus 44.80%), while only a small proportion of patients (176,170: 0.32%) have a missing value for

gender. The proportion of Caucasian patients is higher than non-Caucasians (57.75% versus 42.25%). Patients

between 18-65 years (70.25%) are the majority age group while only a small proportion of patients (870,670:

1.56%) have a missing value for age.   35.51% (19,851,070) of adult patients have private insurance, while

12.61% (7,048,160) are enrolled in Medicare and 6.16% (3,448,710) receive Medicaid. Since the majority of

patients older than 65 years in the US transition from private insurance to Medicare, the Explorys Cohort

Discovery platform contains a study population that represents the general US population and the age-dependent

prevalence of Alzheimer's disease due to the inclusion of Medicare patients. Patients with missing values for

gender or age were excluded when performing statistical analysis.

In the absence of confirmatory brain imaging for amyloid or tau, or pathology post-mortem, the diagnosis of

Alzheimer's disease is a clinical diagnosis made by a physician based on an interview and cognitive assessment.

Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, Alzheimer's disease is

misdiagnosed based solely on clinical criteria in up to 25% of patients [26, 27]. In a database such as the

Explorys Cohort Discovery platform that aggregates EHR from large, integrated health delivery systems and

community-based networks, the rate of misdiagnosis of Alzheimer's disease may be even higher. Therefore, we

structured our analysis to proceed in two stages. We first calculated the AOR for a SNOMED-CT diagnosis of

Alzheimer's disease and second, expanded the analysis using the SNOMED-CT diagnosis of dementia. Within

SNOMED-CT, dementia is a general diagnostic term that includes all patients with a specific diagnosis of

Alzheimer's disease. Within our study population, 338,400 (0.60%) patients were diagnosed with Alzheimer's

disease while 999,800 (1.79%) patients were diagnosed with dementia including Alzheimer's disease. In

addition to Alzheimer's disease, the SNOMED-CT diagnosis of dementia includes subdiagnoses of presenile

dementia, mild, mixed, moderate and severe dementia, dementia associated with human immunodeficiency virus

infection, and frontal temporal lobe dementia, but excludes dementia associated with Huntington's disease,

Parkinson's disease, Rett's syndrome and vascular dementia. The prevalence of Alzheimer's disease in the 2018

US population is estimated at about 2% of persons older than 18 years, so the Explorys study population of

dementia including Alzheimer's disease approximates the prevalence of Alzheimer's disease in the US [28].

Based on prescription history, a substantial number of patients with suspected Alzheimer's disease are likely

classified within the Explorys Cohort Discovery platform with a diagnosis of dementia. For example, the

approved uses of the cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and memantine by the

US Food and Drug Administration (FDA) are for treating mild, moderate or severe dementia of the Alzheimer's

type. Rivastigmine has an additional FDA approval for use in mild-to-moderate dementia associated with

Parkinson's disease. Of 338,400 patients with a diagnosis code for Alzheimer's disease, 172,750 (51%) received

at least one prescription for a cholinesterase inhibitor or memantine, while an additional 157,850 patients with a

diagnosis code for dementia were also treated with at least one drug approved for Alzheimer's disease (24%). A

high proportion of these patients likely represent cases of dementia due to suspected Alzheimer's disease.

Querying more broadly in the Explorys Cohort Discovery platform for any use of a cholinesterase inhibitor or

memantine, 145,860 patients were prescribed at least one of the four drugs without a SNOMED-CT diagnosis of

dementia or Alzheimer's disease. This included 9,540 patients with a diagnosis code for Parkinsonism,

3,900 with a diagnosis code for degenerative disease of the central nervous system, and 3,990 patients with a

diagnosis code for traumatic brain injury. Thus, Explorys captures both approved and off-label use of

prescription drugs.

Risk for Alzheimer's Disease is Increased by Systemic Inflammation

We hypothesized that systemic inflammatory diseases which in part are mediated by TNF increase the risk for

Alzheimer's disease. We therefore selected for study those inflammatory diseases for which a TNF blocking

agent is an FDA approved treatment [5]. Approved indications include rheumatoid arthritis, ankylosing

spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and Crohn's disease.

Five TNF blocking agents have been approved by FDA, of these, sufficient patients were prescribed etanercept

(44,210 patients), adalimumab (66,820 patients), and infliximab (40,290) to allow inclusion in the retrospective,

case-control study. In addition, 161,560 patients received at least one prescription for methotrexate but had not

been treated with a TNF blocking agent. Methotrexate is a small molecule inhibitor of immune cell activation

that suppresses systemic TNF [29]. In normal clinical practice, patients are started on methotrexate and those

who fail methotrexate may progress to a treatment with a TNF blocking agent. Of those who progress to the TNF

blocking agent, 60% will continue on methotrexate and 40% will drop the methotrexate [29, 30].

The cumulative age distribution for patients with a diagnosis code for rheumatoid arthritis, dementia or

Alzheimer's disease is shown in **Figure 2**. Given that the Explorys Cohort Discovery platform includes at least

some information on patients making up over 20% of the US population, the cumulative age distribution should

reasonably represent the age-dependent prevalence of these diseases in the US. As expected, the age distribution

of patients with a diagnosis of rheumatoid arthritis skews younger, while patients with dementia or Alzheimer's

disease skew older. The average treatment retention time varies among the three TNF blocking agents selected

for study with etanercept having a better than 50% patient retention rate at 12 years of treatment, while the 50%

retention rates for adalimumab and infliximab are about 2 and 3 years, respectively [30, 31]. To comply with

HIPAA compliant de-identification of EHR, the Explorys Cohort Discovery platform does not allow patient level

access to prescription data. Therefore, we compared the benefit of etanercept to adalimumab and infliximab as a

surrogate for duration of exposure as a modifier of treatment benefit.

Systemic inflammatory disease is a substantial risk factor for Alzheimer's disease (**Figure 3**). Greatest risk is

associated with inflammatory bowel disease and Crohn's disease followed by rheumatoid arthritis, ulcerative

colitis (as a subcategory of inflammatory bowel disease), ankylosing spondylitis and psoriasis.   There is no

additional risk associated with psoriatic arthritis. Inflammatory bowel disease, Crohn's disease and rheumatoid

arthritis increase the risk for Alzheimer's disease over two-fold (AOR 2.06 (2.02-2.10) – AOR 2.46 (2.33-2.59)).

The increased risk contributed by systemic inflammation was replicated in patients with a diagnosis code for

dementia in which Alzheimer's disease is a subcategory (**Figure 4**). Risk for dementia was elevated two-fold in

patients with rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, ulcerative colitis and

Crohn's disease (AOR 2.00 (1.94-2.06) -AOR 2.69 (2.66-2.72)). Psoriasis also increased risk for Alzheimer's

disease and dementia although to a lesser extent (AOR 1.37 (1.31-1.42) and AOR 1.49 (1.46 – 1.53),

respectively). Thus, systemic inflammation increases risk for Alzheimer's disease across multiple diseases

involving the joints, the gut and the skin.

TNF Blocking Agents Reduce Risk for Alzheimer's Disease in Patients with Systemic Inflammation

If the increased risk for Alzheimer's disease is associated with TNF, then TNF blocking agents should reduce risk

for Alzheimer's disease in patients with co-morbid inflammatory disease. Since TNF blocking agents frequently

are prescribed as an add-on to methotrexate, we compared subjects who received a TNF blocking agent without

methotrexate with those who received the TNF blocking agent and methotrexate. Treatment of rheumatoid

arthritis with etanercept, adalimumab, or infliximab significantly reduced the risk for Alzheimer's disease with

etanercept and adalimumab having the greatest benefit (AOR 0.34 (0.25 – 0.47) and AOR 0.28 (0.19 – 0.39),

respectively), **Figure 5**. The benefit of etanercept and adalimumab was replicated in patients with a diagnosis

code of dementia (AOR 0.30 (0.26 – 0.35) and AOR 0.35 (0.30 – 0.41), respectively). Etanercept and

adalimumab have similar benefit even though the treatment retention time with etanercept (50% at 12 years) is

considerably longer than adalimumab (50% at 2 years) [30, 31]. Infliximab had slightly greater benefit than

methotrexate, but methotrexate alone significantly reduced risk for Alzheimer's disease and dementia (AOR 0.52

(0.39 – 0.69) and AOR 0.64 (0.61 – 0.68), respectively), **Figure 5**. We therefore asked if the benefit of the TNF

blocking agents replicated in patients with a prescription history of a TNF blocker and methotrexate compared to

methotrexate alone. Etanercept and adalimumab had similar benefit in reducing risk for co-morbid Alzheimer's

disease in patients who also had a prescription history for methotrexate (AOR 0.53 (0.42 – 0.67) and AOR 0.61

(0.49 – 0.77), respectively) while the benefit of infliximab was less (AOR 0.77 (0.63 – 0.67), **Figure 6**.

Reduction of risk for Alzheimer's disease also was seen in psoriasis patients treated with a TNF blocking agent

(**Figure 7**). Etanercept (AOR 0.47 (0.30 – 0.73) and adalimumab (AOR 0.41 (0.20 – 0.76) significantly reduced

risk for Alzheimer's disease in patients with psoriasis and the benefit of adalimumab (AOR 0.54 (0.44 – 0.66) was

replicated when expanded to patients with a diagnosis code for dementia (**Figure 7**). Infliximab and methotrexate

had no benefit. A substantial number of psoriasis patients had a prescription history of a TNF blocker with

methotrexate. Methotrexate alone did not reduce risk for Alzheimer's disease, nor did use of a TNF blocker

provide additional benefit adjusting for methotrexate prescription status beyond the benefit of etanercept or

adalimumab alone (AOR 0.53 (0.37 – 0.76) and AOR 0.50 (0.32 – 0.78), **Figure 8**. The Explorys Cohort

Discovery platform does not permit access to patient level data, so a limitation of this analysis is that we do not

know if the TNF blocker was prescribed as an add-on to methotrexate or if the two drugs were prescribed

sequentially with methotrexate dropped once treatment with the TNF blocker was started.

We separately assessed the effects of gender, age, and race on the effect of TNF blocking agents on the risk of

dementia among patients with rheumatoid arthritis. Data are shown for etanercept in **Figure 9**. Female and male

patients had a similar benefit when treated with etanercept ($P = 0.14$), adalimumab ($P = 0.14$), or infliximab ($P =$

0.71). There was a significant difference in benefit when comparing Caucasian versus non-Caucasian patients

with a prescription history for etanercept ($P = 0.022$) but not for adalimumab ($P = 0.34$) or infliximab ($P =$

0.078). Interestingly, the risk reduction was greatly increased for younger patients (18-65 years) as compared to

older patients (> 65 years) with AOR 0.16 (0.11 – 0.22) in younger patients as compared to AOR 0.40 (0.34 –

0.46) in older patients (**Figure 9**). Greater benefit also was seen in younger patients prescribed adalimumab (P =

0.022) or infliximab (P = 0.00026) as compared to older patients.

We also explored insurance status as a potential confound for age (comparing younger patients with private

insurance as compared to patients over 65 years with Medicare) and socioeconomic status (patients with Medicaid

or private insurance). There was no difference between patients with private insurance as compared to Medicare,

nor does adjusting insurance status influence the effect of TNF blockers on the risk for dementia (**Figure 10**).

There were too few patients with Medicaid and Alzheimer's disease (21,030, 6.2%) or Medicaid and a diagnosis

of dementia (84,040, 8.4%) for analysis (**Table 1**).

Finally, we sought to understand if treatment with a TNF blocking agent simply reduced the additional risk for

Alzheimer's disease contributed by a co-morbid inflammatory disease, or if the TNF blocking agent could reduce

risk for Alzheimer's disease below the risk in the general population in the absence of inflammatory disease as a

risk factor and excluding a prescription history for a TNF blocker or methotrexate. Indeed, the risk for

Alzheimer's disease was reduced below the general population risk in rheumatoid arthritis patients treated with

adalimumab (AOR 0.62 (0.43 – 0.89) and in psoriasis patients treated with etanercept (AOR 0.58 (0.37 – 0.90) or

adalimumab (AOR 0.48 (0.23 – 0.88), **Figure 11**. The benefit of adalimumab also replicated for reduction of risk

in psoriasis patients with a diagnosis code for dementia (AOR 0.82 (0.67 – 1.00), **Figure 11**.

Discussion

This study shows that inflammatory diseases involving TNF are associated with increased risk for Alzheimer's

disease. Patients with rheumatoid arthritis, inflammatory bowel disease, or Crohn's disease are at highest risk for

Alzheimer's disease. For rheumatoid arthritis and psoriasis, treatment with a biologic drug that targets TNF

correspondingly reduces the risk for Alzheimer's disease.

This case-control analysis provides an assessment of the additional risk for Alzheimer's disease that can be

attributed to co-morbid inflammatory disease involving TNF. Although there are genetically-defined subgroups

at high risk for Alzheimer's disease, for example, patients with highly penetrant, autosomal dominant APP, PS1

or PS2 mutations,[1] late-onset Alzheimer's disease generally is viewed as a heterogenous disease with multiple

genetic, medical and environmental risk factors [2, 32]. Our analysis suggests that co-morbid inflammatory

disease defines a subgroup of Alzheimer's patients in which systemic production of TNF contributes to

pathogenesis. Systemic TNF may promote neuroinflammation in the brain through receptor-mediated

transcytosis [12]. Biologic drugs such as etanercept and adalimumab distribute poorly to brain, so we presume

the TNF blockers act systemically to prevent TNF from reaching the brain and thereby prevent or delay the onset

of Alzheimer's disease.

Our study indicates that systemic inflammatory conditions involving TNF are a potentially treatable risk factor for

Alzheimer's disease. This is a small, but potentially treatable subgroup of people at risk for Alzheimer's disease.

The total number of patients with Alzheimer's disease in the US is estimated to be 5.3 million in 2018 [28].

Based on our estimate of population attributable risk, 0.21 million cases (4.04%) of Alzheimer's disease might be

preventable by treating rheumatoid arthritis with a TNF blocking agent, 0.08 million cases (1.51%) of

Alzheimer's disease might be preventable by treating Crohn's disease with a TNF blocking agent, and 0.026

million cases (0.50%) of Alzheimer's disease might be preventable by treating psoriasis with a TNF blocker or

nearly 6% of cases of Alzheimer's disease.

Etanercept previously was evaluated in a small, placebo-controlled study enrolling 41 patients with mild-to-

moderate Alzheimer's disease [33]. End points in the study assessed improvement in cognitive function and

activities of daily living. There was a trend for etanercept benefit at 24 weeks of treatment across multiple

assessments. These results are encouraging given the small size of the clinical trial and support further study of

the treatment benefit of etanercept in symptomatic Alzheimer's disease. Etanercept also was evaluated in a small,

open label clinical trial in Alzheimer's disease with report of clinical benefit [34], while therapeutic benefit was

reported earlier for reducing risk of major depression in a pivotal, Phase 3 clinical trial of etanercept for the

treatment of psoriasis [35]. A previous study also suggested that TNF blocking agents are associated with

decreased incidence of co-morbid Parkinson disease in patients with inflammatory bowel disease [36].

Supporting evidence for a role of TNF in Alzheimer's disease comes from the Accelerating Medicines Partnership

– Alzheimer's Disease (AMP-AD), a large-scale, precompetitive public private partnership led by the National

Institute on Aging (NIA). Nominated targets with supporting evidence include multiple elements of the TNF

signaling pathway such as TLR4, NFKBIA, NFKBIZ, TNFSR1A [37]. TLR4 encodes the Toll like receptor 4, a

receptor in microglia, monocytes and macrophages that triggers TNF release when activated by

lipopolysaccharide, or in the case of microglia, by amyloid beta peptide [32]. TLR4 and a second Toll-like

receptor, TLR5, are upregulated in the Alzheimer's brain and soluble fragments have been shown to act as decoy

receptors to ameliorate disease phenotypes in a transgenic mouse model of Alzheimer's disease [38]. NFKBIA

and NFKBIZ are components of the nuclear I kappa B protein signaling pathway that regulates the expression of

TNF while TNFSR1A encodes the TNF receptor superfamily member 1A that is activated by TNF [39].

Microglia activation and gliosis formerly were considered secondary to neurodegeneration in Alzheimer's

disease, however, recent genetic studies in late-onset Alzheimer's disease implicate microglia- and astrocyte-

related pathways in disease pathogenesis.[10, 40, 41] One focus of interest is TREM2, an innate immune receptor

expressed on microglia and myeloid cells [42, 43] . Rare TREM2 mutations associated with Alzheimer's disease

suggest that TREM2 deficiency contributes to Alzheimer's disease risk [44, 45]. TREM2 is a negative regulator

of the release of TNF and other inflammatory cytokines through activation of the Toll-receptor pathway [8, 43,

46].

TNF signaling can be targeted by small molecule therapeutics [7, 9, 47]. For example, this pathway is modulated

in monocytes, macrophages and microglia by phosphodiesterase-4B (PDE4B) [48, 49], while treatment with a

PDE4B allosteric inhibitor after acute brain injury reduces microglial activation, reduces production of TNF, and

provides neuroprotective benefit in rats [50]. Small molecule drugs targeting the TLR4-TNF pathway may

produce greater therapeutic benefit than large, biologic drugs for which brain penetration may be limited.

Epidemiologic studies previously suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the

risk for Alzheimer's disease [51]. In a case-control study of 49,349 US Veterans, protective effects were seen with

ibuprofen, naproxen and other NSAIDs with > 5 years of use (OR 0.76 [0.68-0.85]). Use of an NSAID was most

frequently associated with osteoarthritis (46-48% of cases and controls). The risk reduction associated with use of

an NSAID was less than the risk reduction of Alzheimer's disease due to use of methotrexate in patients with

rheumatoid arthritis (OR 0.51 [0.49-0.54]), **Figure 3**. Multiple randomized, placebo-controlled clinical trials have

failed to show benefit of treatment with an NSAID in prodromal or symptomatic Alzheimer's disease [52-54].

NSAIDs are one of three categories of therapeutics used to treat rheumatoid arthritis.[5] The other categories are

corticosteroids and disease-modifying antirheumatic drugs (DMARDs). NSAIDs are used for the control of pain

and inflammation while corticosteroids and DMARDs are used to reduce the cellular immune response that leads

to destruction of the joint. NSAIDs suppress prostaglandin synthesis by inhibiting the cyclooxygenase enzymes

COX-1 and COX-2, and thereby reduce immune cell activation, but may increase TNF production [47, 55]. The

lack of efficacy seen with NSAIDs in Alzheimer's disease may be associated with the lack of a strong suppressive

effect on TNF production. Low dose prednisone (10 mg/day) is used to treat rheumatoid arthritis, presumably by

suppressing immune activation and TNF production, but long term use is associated with increasingly

unacceptable side effects. Treatment with low dose prednisone for 1 year failed to show benefit in patients with

mild-to-moderate Alzheimer's disease [56].

Strengths and Limitations

The strength of the current study is that the massive-scale of the EHR database allowed us to access real-world

patient populations. With 64 million unique patient EHR, the IBM Watson Health Explorys Cohort Discovery

platform has aggregated the medical records from approximately 20% of the US population. Such a massive

database covers the full spectrum of disease diagnoses and the use of prescription drugs for both approved and

off-label indications. Access to large data sets is particularly useful in the case of Alzheimer's disease where a

substantial fraction of patients in a clinical setting are either misdiagnosed as having the disease when they do not

or for whom the physician is unwilling to make a specific diagnosis even though Alzheimer's disease is suspected

and an approved medication for Alzheimer's disease is prescribed. This allowed us to test for the association of

co-morbid Alzheimer's disease with systemic inflammatory disease and to test the benefit of TNF blocking agents

by first selecting patient cohorts with a specific diagnosis of Alzheimer's disease and then by replicating that

finding in a larger cohort of patients with dementia which better reflects the uncertainty of the diagnosis of

Alzheimer's disease in a community health setting.

The scale of the Watson Health Explorys Cohort Discovery platform allowed us to maintain adequate statistical

power while we studied disease association and the benefit of TNF blockers across multiple inflammatory

diseases. This often is difficult in traditional observational studies which frequently are limited in sample size.

Compared to the private insurance database used in the previous study [13], the Explorys Cohort Discovery

platform contains a study population that includes patients with private insurance and Medicare. This is

particularly critical for the study of diseases that primarily affect an elderly population as the majority of patients

older than 65 years in the US transition from private insurance to Medicare.

The current study has limitations. First, the quality or incompleteness of the EHR for individual patients may

affect the sensitivity and specificity of the analysis and misdiagnosis will contribute to false positives and false

negatives within the patient cohorts selected for study Second, the retrospective case-control analysis suggests a

potential therapeutic benefit of TNF blocking agents in Alzheimer's disease, however, the analysis does not

distinguish an effect on treatment of prevention, nor does our analysis address how the severity of disease may

influence benefit. A limitation of the Explorys Cohort Discovery platform is the inability to access patient level

data for reasons of confidentiality. We are unable to extract age at diagnosis, duration of treatment, or years of

follow up which are potential confounding factors to this analysis, nor are we able to build an exposure-response

relationship for the reduction in risk due to use of a TNF blocking agent. Due the fact that we used population-

level data, we relied on the odds ratio for the statistical analysis and cannot calculate an incidence rate ratio [36].

Additionally, the Explorys Cohort Discovery platform considers patients to be "taking a medication" if at least on

outpatient prescription has been written for the medication, but does not record if medications were prescribed

sequentially after the first drug failed, or whether two or more medications were prescribed concurrently. These

potential confounds may lead our findings to underrepresent the "true findings." Without access to patient level

data, we were only able to control for known confounding factors using the Cochran-Mantel-Haenszel (CMH)

method [25] instead of systematically identifying and controlling for potential confounding factors using a more

rigorous multivariable regression method. Even with these limitations, the results of our study are consistent with

a previous study using patient-level data [13] and with a unpublished study reported in the popular press. As

shown in **Table 2**, the therapeutic benefit of etanercept on risk for co-morbid Alzheimer's disease that we report

in patients with rheumatoid arthritis is consistent with a previous case-control analysis of 8.5 million privately

insured patients [13] and with an unpublished study that reportedly analyzed claims data from 254,000 patients.

Thus, our study conducted with a massive EHR database is consistent with smaller studies conducted with

patient-level data collected using private insurance claims databases.

Conclusions

Our analysis demonstrates the value of a large, population-based database aggregating EHR from nearly 56

million adult patients for the rapid interrogation of the treatment benefit of prescription drugs. Patients diagnosed

with a systemic inflammatory disease are at increased risk for developing Alzheimer's disease, while TNF

blocking agents reduce the risk for co-morbid Alzheimer's disease in real-world patients diagnosed with

rheumatoid arthritis or psoriasis.

Author Information

Author Contributions

M.Z. conducted the statistical analysis. R.X. designed the study. D.C.K contributed to the manuscript. M.E.G.

coauthored the manuscript.

Acknowledgements

The authors thank Dr Susan Petanscka PhD, Dr Scott Reines MD PhD and Dr Richard Martin MD for their

comments on the design of the study.

Conflict of Interest Disclosures

M.Z., R.X. and M.E.G have no financial interest in etanercept, adalimumab, or infliximab. M.E.G is an employee

of Tetra Therapeutics.

Funding/Support

R.X. acknowledges support from Eunice Kennedy Shriver National Institute of Child Health & Human

Development of the National Institutes of Health under the NIH Director's New Innovator Award number

DP2HD084068, NIH National Institute of Aging R01 AG057557, R01 AG061388, R56 AG062272 and American

Cancer Society Research Scholar Grant RSG-16-049-01 – MPC; M.E.G. is an employee of Tetra Discovery

Partners, Inc. and acknowledges support from the National Institute of Mental Health awards MH091791 and

MH107077.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection,

management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and

decision to submit the manuscript for publication.

Meeting Presentation: Portions of this study were presented at the National Institute on Aging-Alzheimer's

Association symposium on "Enabling Precision Medicine For Alzheimer's Disease Through Open Science", July

11-July 12, 2019, Los Angeles, California.

OCRID ID

Rong Xu: 0000-0003-3127-4795

Mark Gurney: 0000-0003-4901-3083

Tables

Table 1. Baseline characteristics of the study population

Patient Characteristics	Study Population	Alzheimer's Disease	Dementia
Total No. of patients	55,954,070	338,400	999,800
Gender (Number (%))			
Female	30,708,300 (54.88)	216,530 (63.99)	605,350 (60.55)
Male	25,069,350 (44.80)	121,770 (35.98)	394,110 (39.42)
Unknown	176,410 (0.32)	100 (0.030)	330 (0.030)
Age (Number (%))			
Adult (18 to 65)	39,294,220 (70.23)	13,300 (3.93)	151,130 (15.12)
Senior (> 65)	15,788,180 (28.22)	308,930 (91.29)	810,180 (81.03)
Unknown	850,590 (1.52)	16,120 (4.76)	38,230 (3.82)
Race (Number (%))			
Caucasian	32,209,260 (57.56)	263,850 (77.94)	773,810 (77.40)
Non-Caucasian	23,744,810 (42.44)	74,560 (22.03)	225,990 (22.60)
Insurance (Number (%))			
Private	19,854,540 (35.48)	112,350 (33.20)	351,420 (35.15)
Medicare	7,047,380 (12.59)	213,760 (63.17)	578,670 (57.88)
Medicaid	3,448,710 (6.16)	21,030 (6.21)	84,040 (8.41)
Diagnoses (Number (%))			
Rheumatoid arthritis	514,440 (0.92)	16,280 (4.81)	47,270 (4.73)
Ankylosing spondylitis	35,550 (0.060)	460 (0.14)	1,620 (0.16)
Psoriasis	309,660 (0.55)	3,340 (0.99)	10,500 (1.05)
Psoriatic arthritis	80,580 (0.14)	650 (0.19)	2,220 (0.22)
Inflammatory bowel disease	279,040 (0.50)	4,440 (1.31)	13,770 (1.38)
Ulcerative colitis	168,870 (0.30)	2,650 (0.78)	8,220 (0.82)
Crohn's disease	201,870 (0.36)	6,160 (1.82)	12,270 (1.23)
Drugs (Number (%))			
Etanercept	44,210 (0.080)	250 (0.070)	1,080 (0.11)
Adalimumab	66,820 (0.12)	320 (0.090)	1,260 (0.13)
Infliximab	40,290 (0.070)	340 (0.10)	1,100 (0.11)
Methotrexate	216,200 (0.39)	2,850 (0.84)	9,550 (0.96)

459 **Table 2:** Comparison of etanercept, adalimumab, and infliximab benefit across studies.

Study	Sample size	Outcome	TNF Blockers	OR	*P*-value
Chou 2016 [13]	8.5 million	Alzheimer's disease	etanercept	0.30	0.02
The Washington Post$^\$$	254,000	Alzheimer's disease	etanercept	0.36	<0.0001
Our study	56 million	Alzheimer's disease	etanercept	0.34	<0.0001
Our study	56 million	Dementia	etanercept	0.30	<0.0001
Chou 2016 [13]	8.5 million	Alzheimer's disease	adalimumab	0.65	0.71
Our study	56 million	Alzheimer's disease	adalimumab	0.28	<0.0001
Our study	56 million	Dementia	adalimumab	0.35	<0.0001
Chou 2016 [13]	8.5 million	Alzheimer's disease	infliximab	0.73	0.68
Our study	56 million	Alzheimer's disease	infliximab	0.64	<0.0001
Our study	56 million	Dementia	infliximab	0.47	<0.0001

$^\$$https://www.washingtonpost.com/business/economy/pfizer-had-clues-its-blockbuster-drug-could-prevent-
alzheimers-why-didnt-it-tell-the-world/2019/06/04/9092e08a-7a61-11e9-8bb7-0fc796cf2ec0_story.html

Figures

Figure 1. A screen shot of cohort identification using the IBM Watson Health Explorys Cohort Discovery fast

search tool. This example selects female Caucasian patients with age > 65 years with a diagnosis code for

dementia and a prescription for etanercept (Enbrel).

471 **Figure 2.** Cumulative age distribution of patients with a diagnosis code for rheumatoid arthritis, dementia or

472 Alzheimer's disease.

474
475

476 **Figure 3.** Adjusted Odds Ratio (AOR) for a diagnosis of Alzheimer's disease associated with a diagnosis for an

477 inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid

478 arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative

479 colitis, Crohn's -Crohn's disease

481
482
483

484   **Figure 4.** Adjusted Odds Ratio (AOR) for a diagnosis code of dementia associated with a diagnosis for an

485   inflammatory diseases as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid

486   arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative

487   colitis, Crohn's -Crohn's disease.

492   **Figure 5.** Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer's disease or a diagnosis of

493   dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of a TNF blocker or

494   methotrexate compared to the no-drug group. The analysis excluded patients with a prescription history of a TNF

495   blocker and methotrexate.

Drug	Outcome	AOR(95% CI)	P-value
Etanercept	Alzheimer	0.34 (0.25,0.47)	<0.0001
Adalimumab	Alzheimer	0.28 (0.19,0.39)	<0.0001
Infliximab	Alzheimer	0.52 (0.39,0.69)	<0.0001
Methotrexate	Alzheimer	0.64 (0.61,0.68)	<0.0001
Etanercept	Dementia	0.30 (0.26,0.35)	<0.0001
Adalimumab	Dementia	0.35 (0.30,0.41)	<0.0001
Infliximab	Dementia	0.47 (0.40,0.55)	<0.0001
Methotrexate	Dementia	0.58 (0.56,0.60)	<0.0001

Higher odds for no drug group   Higher odds for drug group

AOR axis: 0 0.1 0.3 0.5 0.7 0.9 1 1.1 1.3 1.5 1.7

AOR

Figure 6: Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer's disease or a diagnosis of

dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of methotrexate and a

TNF blocker compared to the methotrexate and no-TNF blocker group.

Figure 7. Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer's disease or a diagnosis of

dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker or methotrexate

compared to the no-drug group.

Figure 8. Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer's disease or a diagnosis of

dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker adjusting for

methotrexate prescription status.

518   **Figure 9.** Effect of age, gender and race on risk for a diagnosis of dementia in rheumatoid arthritis patients treated

519   with etanercept. Young patients (18-65 years) showed greater benefit than did older patients (over 65 years). The

520   effect of gender and race was not significant.

Subgroup	Subgroup count	OR (95% CI)	P-value
Overall	7530	0.27 (0.23,0.31)	<0.0001
Gender			
Female	5350	0.29 (0.24,0.33)	<0.0001
Male	2180	0.23 (0.17,0.29)	<0.0001
Age			
18-65	4500	0.16 (0.11,0.22)	<0.0001
> 65	3000	0.40 (0.34,0.46)	<0.0001
Race			
Caucasian	6350	0.25 (0.21,0.29)	<0.0001
Non-caucasian	1180	0.37 (0.26,0.41)	<0.0001

Higher odds for no drug group Higher odds for drug group

0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
AOR

522
523

524 **Figure 10.** Crude Odds Ratios (OR) and Adjusted Odds Ratios (AOR) based on insurance status (Medicare versus

525 no-Medicare, or private versus no-private insurance) in patients with a diagnosis code for dementia and

526 rheumatoid arthritis.

Drug	Age	Insurance	AOR(95% CI)	P-value
Etanercept	>65	no adjust	0.39 (0.34,0.46)	<0.0001
Etanercept	>65	adjust Medicare	0.41 (0.36,0.48)	<0.0001
Adalimumab	>65	no adjust	0.41 (0.34,0.48)	<0.0001
Adalimumab	>65	adjust Medicare	0.41 (0.35, 0.49)	<0.0001
Infliximab	>65	no adjust	0.51 (0.44,0.61)	<0.0001
Infliximab	>65	adjust Medicare	0.45 (0.38,0.54)	<0.0001
Adalimumab	18-65	no adjust	0.33 (0.23,0.45)	<0.0001
Adalimumab	18-65	adjust private	0.35 (0.26,0.48)	<0.0001
Etanercept	18-65	no adjust	0.14 (0.08,0.21)	<0.0001
Etanercept	18-65	only private	0.24 (0.15,0.38)	<0.0001

Higher odds for no drug gorup | Higher odds for drug group

00.1 0.3 0.5 0.7 0.911.1 1.3 1.5 1.7
AOR

530 **Figure 11.** Comparison of the risk for a diagnosis of Alzheimer's disease or dementia in patients with a diagnosis

531 of rheumatoid arthritis or psoriasis with a prescription history for etanercept, adalimumab, or infliximab who were

532 not prescribed methotrexate against the general population.

Drug	Diagnose(drug group)	Outcome	AOR(95% CI)	P-value
Etanercept	Rheumatoid arthritis	Alzheimer	0.75 (0.55,1.02)	0.078
Adalimumab	Rheumatoid arthritis	Alzheimer	0.62 (0.43,0.89)	0.011
Infliximab	Rheumatoid arthritis	Alzheimer	1.17 (0.89,1.55)	0.3
Etanercept	Rheumatoid arthritis	Dementia	1.08 (0.94,1.25)	0.27
Adalimumab	Rheumatoid arthritis	Dementia	1.30 (1.12,1.5)	0.00051
Infliximab	Rheumatoid arthritis	Dementia	1.37 (1.17,1.61)	0.00014
Etanercept	Psoriasis	Alzheimer	0.58 (0.37,0.90)	0.019
Adalimumab	Psoriasis	Alzheimer	0.48 (0.23,0.88)	0.014
Infliximab	Psoriasis	Alzheimer	1.32 (0.63,2.47)	0.36
Etanercept	Psoriasis	Dementia	1.30 (1.10,1.55)	0.0025
Adalimumab	Psoriasis	Dementia	0.82 (0.67 ,1.00)	0.049
Infliximab	Psoriasis	Dementia	0.92 (0.64,1.33)	0.74

Higher odds for general population   Higher odds for drug use group

0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4
AOR

534
535

S8 Table. Two by two tables calculating the insurance status-adjusted and crude ORs of dementia for each TNF

blocker use group compared to the non-drug use group in patients with a diagnosis of rheumatoid arthritis. The

analysis excluded patients with a prescription history of a TNF blocker and methotrexate.

S9 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or

dementia in rheumatoid arthritis or psoriasis patients who have prescribed a TNF blocker but no methotrexate

prescription history against the general population.

References

1.   Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease.

Lancet. 2016;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. PubMed PMID: 26921134.

2.   Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research

Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62. doi:

10.1016/j.jalz.2018.02.018. PubMed PMID: 29653606; PubMed Central PMCID: PMCPMC5958625.

3.   Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459-72.

doi: 10.1083/jcb.201709069. PubMed PMID: 29196460; PubMed Central PMCID: PMCPMC5800817.

4.   Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that

adult microglia derive from primitive macrophages. Science. 2010;330(6005):841-5. doi:

10.1126/science.1194637. PubMed PMID: 20966214; PubMed Central PMCID: PMCPMC3719181.

5.   Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune

diseases. Transl Res. 2015;165(2):270-82. doi: 10.1016/j.trsl.2014.09.006. PubMed PMID: 25305470.

6.   Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of

Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200. PubMed

PMID: 12933918; PubMed Central PMCID: PMCPMC1738668.

7.   Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discov

Today. 2014. doi: 10.1016/j.drudis.2014.06.029. PubMed PMID: 24998784.

8.   Long H, Zhong G, Wang C, Zhang J, Zhang Y, Luo J, et al. TREM2 Attenuates Abeta1-42-Mediated

Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling. Neurochem Res. 2019;44(8):1830-9. doi:

10.1007/s11064-019-02817-1. PubMed PMID: 31134514.

9.   McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the

pathophysiology of Alzheimer's disease. J Inflamm Res. 2008;1:29-39. PubMed PMID: 22096345; PubMed

Central PMCID: PMCPMC3218716.

10.   Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive

astrocytes are induced by activated microglia. Nature. 2017;541(7638):481-7. doi: 10.1038/nature21029. PubMed

PMID: 28099414; PubMed Central PMCID: PMCPMC5404890.

11.   Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice

expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025-31.

PubMed PMID: 1721867; PubMed Central PMCID: PMCPMC453150.

12.   Pan W, Kastin AJ. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout

mice. Exp Neurol. 2002;174(2):193-200. doi: 10.1006/exnr.2002.7871. PubMed PMID: 11922661.

13.   Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of

Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs. 2016;30(11):1111-20. doi: 10.1007/s40263-

016-0374-z. PubMed PMID: 27470609; PubMed Central PMCID: PMCPMC5585782.

14.   Kaelber DC, Foster W, Gilder J, Love TE, Jain AK. Patient characteristics associated with venous

thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc.

2012;19(6):965-72. doi: 10.1136/amiajnl-2011-000782. PubMed PMID: 22759621; PubMed Central PMCID:

PMCPMC3534456.

15.   Patel VN, Kaelber DC. Using aggregated, de-identified electronic health record data for multivariate

pharmacosurveillance: a case study of azathioprine. J Biomed Inform. 2014;52:36-42. doi:

10.1016/j.jbi.2013.10.009. PubMed PMID: 24177317; PubMed Central PMCID: PMCPMC4002671.

16.   Winhusen T, Theobald J, Kaelber DC, Lewis D. Medical complications associated with substance use

disorders in patients with type 2 diabetes and hypertension: electronic health record findings. Addiction. 2019.

doi: 10.1111/add.14607. PubMed PMID: 30851217.

17.   Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric

protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174(6):1483-9. doi: 10.1084/jem.174.6.1483.

PubMed PMID: 1660525; PubMed Central PMCID: PMCPMC2119031.

18.   Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human

antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y). 1994;12(9):899-

903. PubMed PMID: 7521646.

19.   Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial

characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443-53. PubMed

PMID: 8232330.

20.   Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61. Epub 2007/01/03.

doi: 10.1016/j.drudis.2006.10.013. PubMed PMID: 17198973.

21.   Lindberg C. The Unified Medical Language System (UMLS) of the National Library of Medicine. J Am

Med Rec Assoc. 1990;61(5):40-2. PubMed PMID: 10104531.

22.   Millar J. The Need for a Global Language - SNOMED CT Introduction. Stud Health Technol Inform.

2016;225:683-5. PubMed PMID: 27332304.

23.   Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6

years. J Am Med Inform Assoc. 2011;18(4):441-8. doi: 10.1136/amiajnl-2011-000116. PubMed PMID:

21515544; PubMed Central PMCID: PMCPMC3128404.

24.   Huff SM, Rocha RA, McDonald CJ, De Moor GJ, Fiers T, Bidgood WD, Jr., et al. Development of the

Logical Observation Identifier Names and Codes (LOINC) vocabulary. J Am Med Inform Assoc. 1998;5(3):276-

92. doi: 10.1136/jamia.1998.0050276. PubMed PMID: 9609498; PubMed Central PMCID: PMCPMC61302.

25.   Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: applications and

recent developments. Annu Rev Public Health. 1988;9:123-60. doi: 10.1146/annurev.pu.09.050188.001011.

PubMed PMID: 3288229.

26.   Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of

bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-33. doi:

10.1056/NEJMoa1304839. PubMed PMID: 24450891.

27.   Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for

mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311-21. doi: 10.1056/NEJMoa1312889.

PubMed PMID: 24450890.

28.   Alzheimer's A. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12(4):459-509.

PubMed PMID: 27570871.

29.   Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA.

2018;320(13):1360-72. doi: 10.1001/jama.2018.13103. PubMed PMID: 30285183.

30.   Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-Year

Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a

Local Registry. Arthritis Care Res (Hoboken). 2016;68(4):432-9. doi: 10.1002/acr.22788. PubMed PMID:

26556048.

31.   Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, et al. Eight-year

survival study of first-line tumour necrosis factor alpha inhibitors in rheumatoid arthritis: real-world data from a

university centre registry. Rheumatol Adv Pract. 2019;3(1):rkz007. doi: 10.1093/rap/rkz007. PubMed PMID:

31431995; PubMed Central PMCID: PMCPMC6649942.

32.   Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation

in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. PubMed

PMID: 25792098; PubMed Central PMCID: PMCPMC5909703.

33.   Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer

disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161-8. doi:

10.1212/WNL.0000000000001617. PubMed PMID: 25934853; PubMed Central PMCID: PMCPMC4451045.

34.   Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's

disease: a 6-month pilot study. MedGenMed. 2006;8(2):25. PubMed PMID: 16926764; PubMed Central PMCID:

PMCPMC1785182.

35.   Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes,

fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet.

2006;367(9504):29-35. doi: 10.1016/S0140-6736(05)67763-X. PubMed PMID: 16399150.

36.   Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti-Tumor Necrosis Factor Therapy and

Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurol.

2018;75(8):939-46. doi: 10.1001/jamaneurol.2018.0605. PubMed PMID: 29710331; PubMed Central PMCID:

PMCPMC6142934.

37.   Gurney ME, D'Amato EC, Burgin AB. Phosphodiesterase-4 (PDE4) Molecular Pharmacology and

Alzheimer's Disease. Neurotherapeutics. 2014. doi: 10.1007/s13311-014-0309-7. PubMed PMID: 25371167.

38.   Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, et al. TLR5 decoy receptor as a

novel anti-amyloid therapeutic for Alzheimer's disease. J Exp Med. 2018;215(9):2247-64. doi:

10.1084/jem.20180484. PubMed PMID: 30158114; PubMed Central PMCID: PMCPMC6122970.

39.   Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects.

Neuroscience. 2015;302:2-22. doi: 10.1016/j.neuroscience.2015.06.038. PubMed PMID: 26117714.

40.   Chung WS, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in

disease? Nat Neurosci. 2015;18(11):1539-45. doi: 10.1038/nn.4142. PubMed PMID: 26505565; PubMed Central

PMCID: PMCPMC4739631.

41.   Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018-

27. doi: 10.1038/nm.4397. PubMed PMID: 28886007.

42.   Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding

variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.

Nat Genet. 2017;49(9):1373-84. doi: 10.1038/ng.3916. PubMed PMID: 28714976; PubMed Central PMCID:

PMCPMC5669039.

43.   Yeh FL, Hansen DV, Sheng M. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med.

2017;23(6):512-33. doi: 10.1016/j.molmed.2017.03.008. PubMed PMID: 28442216.

44.   Jiang T, Zhang YD, Chen Q, Gao Q, Zhu XC, Zhou JS, et al. TREM2 modifies microglial phenotype and

provides neuroprotection in P301S tau transgenic mice. Neuropharmacology. 2016;105:196-206. doi:

10.1016/j.neuropharm.2016.01.028. PubMed PMID: 26802771.

45.   Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al. TREM2 deficiency exacerbates

tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener.

2017;12(1):74. doi: 10.1186/s13024-017-0216-6. PubMed PMID: 29037207; PubMed Central PMCID:

PMCPMC5644120.

46.   Gorenjak V, Aldasoro Arguinano AA, Dade S, Stathopoulou MG, Vance DR, Masson C, et al. The

polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-alpha

levels and IMT-F. Sci Rep. 2018;8(1):7160. doi: 10.1038/s41598-018-25553-y. PubMed PMID: 29740051.

47.   Li P, Zheng Y, Chen X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule

Compounds to Anti-TNF Biologics. Front Pharmacol. 2017;8:460. doi: 10.3389/fphar.2017.00460. PubMed

PMID: 28785220; PubMed Central PMCID: PMCPMC5506195.

48.   Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-

activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99(11):7628-33. Epub 2002/05/29. doi:

10.1073/pnas.122041599. PubMed PMID: 12032334.

49.   Ghosh M, Garcia-Castillo D, Aguirre V, Golshani R, Atkins CM, Bramlett HM, et al. Proinflammatory

cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

Glia. 2012. doi: 10.1002/glia.22401. PubMed PMID: 22865690.

50.   Wilson NM, Gurney ME, Dietrich WD, Atkins CM. Therapeutic benefits of phosphodiesterase 4B

inhibition after traumatic brain injury. PLoS One. 2017;12(5):e0178013. doi: 10.1371/journal.pone.0178013.

PubMed PMID: 28542295; PubMed Central PMCID: PMCPMC5438188.

51.   Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of

Alzheimer disease. Neurology. 2008;70(19):1672-7. doi: 10.1212/01.wnl.0000311269.57716.63. PubMed PMID:

18458226; PubMed Central PMCID: PMCPMC2758242.

52.   Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, Team AR. Effects of non-steroidal anti-

inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from

the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry.

2012;27(4):364-74. doi: 10.1002/gps.2723. PubMed PMID: 21560159; PubMed Central PMCID:

PMCPMC3208130.

53.   Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan ME, Savard M, et al.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology.

2019;92(18):e2070-e80. doi: 10.1212/WNL.0000000000007232. PubMed PMID: 30952794; PubMed Central

PMCID: PMCPMC6512884.

54.   Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on

Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71. doi:

10.1212/wnl.62.1.66. PubMed PMID: 14718699.

55.   Page TH, Turner JJ, Brown AC, Timms EM, Inglis JJ, Brennan FM, et al. Nonsteroidal anti-inflammatory

drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol.

2010;185(6):3694-701. doi: 10.4049/jimmunol.1000906. PubMed PMID: 20713883.

56.   Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial

of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54(3):588-93.

doi: 10.1212/wnl.54.3.588. PubMed PMID: 10680787.